Keywords
sodium-glucose cotransporter 2 inhibitors
older adult
anemia
chronic kidney disease
hyponatremia
syndrome of inappropriate antidiuretic hormone secretion
How to Cite
Abstract
Hyponatremia is a common electrolyte disorder in older adults, with a prevalence between 15 % and 30 % in hospitalized patients. It is classified as hypovolemic, euvolemic, or hypervolemic. The euvolemic type is often associated with the syndrome of inappropriate antidiuretic hormone secretion, surgical stress, or glucocorticoid deficiency. This case report presents a 95-year-old woman with chronic hypotonic euvolemic hyponatremia and anemia, both refractory to conventional treatment. After initiating empagliflozin 10 mg/day, improvements were observed in serum sodium, blood pressure, proteinuria, and hemoglobin levels over a four-month follow-up. This case highlights the potential role of sodium-glucose cotransporter 2 inhibitors as a treatment option in older adults with chronic euvolemic hyponatremia, especially in those with chronic kidney disease, albuminuria, and anemia resistant to standard therapies. While the results are promising, further clinical evidence is needed to support the routine use of SGLT2 inhibitors in similar clinical scenarios.
References
Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier C, Sterns R, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Supl 1):1-42.
Schlanger LE, Bailey JL, Sands JM. Electrolytes in the Aging. Adv Chronic Kidney Dis. 2010;17(4):308-319.
Burguera V, Rodríguez-Palomares JR, Fernández-Codejón O, Tenorio MT, del Rey JM, Liaño F. Epidemiología de la hiponatremia. Nefrología. 2011;2(6):13-20.
Diaztagle-Fernández JJ, Chaves-Saltiago WG, Sprockel-Díaz JJ, Acevedo-Velasco AD, Rodríguez-Benítez FH, Benavides-Solarte MF, et al. Asociación entre hiponatremia, mortalidad y estancia hospitalaria en pacientes con falla cardíaca descompensada. MedUNAB. 2019;22(3):294-303.
Chica DA, Roa NC, Contrera VM. Hiponatremia en pacientes hospitalizados con insuficiencia cardiaca descompensada en una IPS de Barranquilla [trabajo de grado]. Barranquilla: Universidad Simón Bolívar; 2020 [citado 2024 jun 27]. Disponible en: https://bonga.unisimon.edu.co/items/5decf962-1b84-4614-908a-22745fad5254
Moran D, Fronk C, Mandel E. Managing hyponatremia in adults. JAAPA. 2014;27(4):23-29.
Musialik D, Raszeja-Wanic B, Boruczkowska A. Hyponatremia and hypernatremia in the elderly. Pol Tyg Lek. 1994;49(10-11):235-238.
Filippatos TD, Liamis G, Christopoulou F, Elisaf MS. Ten common pitfalls in the evaluation of patients with hyponatremia. Eur J Intern Med. 2016;29:22-25.
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1-47.
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Guía de práctica clínica sobre el diagnóstico y tratamiento de la hiponatremia. Nefrología. 2017;37(4):357-460.
Monnerat S, Atila C, Refardt J, Christ-Crain M. Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor. J Endocr Soc. 2023;7(4):1-8.
Refardt J, Winzeler B, Meienberg F, Vogt D, Christ-Crain M. Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis. Int J Endocrinol. 2017;2017:1-7.
Zhou Y, Yang W, Liu G, Gao W. Risks of vaptans in hypernatremia and serum sodium overcorrection: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75(6).
Refardt J, Imber C, Sailer C, Jeanloz N, Potasso L, Kutz A, et al. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. J Am Soc Nephrol. 2020;31(3):615-624.
Refardt J, Imber C, Nobbenhuis R, Sailer C, Haslbauer A, Monnerat S, et al. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Am Soc Nephrol. 2023;34(2):322-332.
Morales D, Obregón A, Pérez M, Zanabria P, Fanghänel G, Sánchez L. iSGLT2 y su potencial efecto nefroprotector en pacientes con diabetes mellitus 2. Med. interna de Méx. 2017;33(4):503-510.
Gómez J, Montes M, González J. El futuro en investigación y qué esperar de los inhibidores del cotransportador de sodio-glucosa tipo 2 -i-SGLT2-. Rev Colomb Cardiol. 2020;27(S2):40-44.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357.
McMurray J, Solomon S, Inzucchi S, Køber L, Kosiborod M, Martinez F, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.
Anker S, Butler J, Filippatos G, Ferreira J, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461.
Pollack R, Cahn A. SGLT2 Inhibitors and Safety in Older Patients. Heart Fail Clin. 2022;18(4):635-643.
Monnerat S, Atila C, Refardt J, Christ-Crain M. Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor. J Endocr Soc. 2023;7(4).
Castellanos L, Cárdenas L, Carrillo ML. Revisión Hiponatremia. Horiz. Med. 2016;16(4):60-71.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424.
Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Monnerat S, et al. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Am Soc Nephrol. 2023;34(2):322-332.
Bioletto F, Varaldo E, Prencipe N, Benso A, Berton AM. Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review. Hormones (Athens). 2023;22(2):343-347.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306.
Ferreira JP, Anker SD, Butler J, Filippatos G, Iwata T, Salsali A, et al. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail. 2022;24(4):708-715.
Okonogi H, Harada M, Sato H, Tokoro K, Nakayama I, Tsuboi N, et al. Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury. Intern Med. 2016;55(14):1887-1891.
Fernández-Trujillo Moujir C, Sánchez García AM, Marrero Arencibia D, Alberiche Ruano MP, Morón Díaz M, González Lleó AM, et al. Tratamiento de la hiponatremia con un inhibidor del cotransportador sodio-glucosa tipo 2 (i-SGLT2) en un paciente con SIADH crónico y diabetes tipo 2. Endocrinol Nutr. 2016;63(Espec Cong 2):366.
Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, et al. Characterization and implications of the initial estimated glomerular filtration rate “dip” upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99(3):750-762.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127.
Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med. 2019;131(1):31-42.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Médicas UIS